Free Financial Information

Since Kalorama Information last comprehensive update of our report for market trials of cancer, changes in industry abound. Developments that are new two years ago, such as marketing of products or services, PGX and evidence of tissue microarrays show a greater presence. Some companies that promised much in the final results have not been place. And the newcomers have entered the field. These changes and others are treated worldwide Kalorama Information market for cancer diagnostics, fourth. Edition. This report from Kalorama analyst Shara Rosen diagnosis contains Detailed market data in the following segments for IVD use in the diagnosis of cancer: • Histology / Cytology • • immunoassay flow cytometry • • • Molecular analysis for rapid screening tests surrounding tissues • • Dies Tumor Cells Pharmacognosy diagnostic to detect how reliable cancer are clearly needed more than ever. As cancer becomes more easy to deal with multiple diagnoses functions, including research related to wider pharmacognosy patient-specific treatment and monitoring of disease during the cancer can be treated enters the field of chronic diseases. Kalorama Worldwide Market Information Cancer Diagnosis, 4th edition is the fourth time Kalorama has participated in a comprehensive study on the status of this important diagnostic market. Among market data in this report, readers will find: • cancer immunoassay laboratory sales volumes • Pap • Global cancer statistics • • Reagents for DNA testing for cancer CDW • • Test Test Innovations Biochips Markets • The CTC New companies • Novel Approaches “laggards” Companies that do not meet expectations • major protein and molecular markers used in the dyeing of fabrics, biomarkers • Low • • Mergers and Acquisitions Research Status PGX testing • Microarray Markets in clinical laboratories • lists of suppliers and main products • Unmet Marketplace The report includes a market analysis of the following projection: the cancer profile of the CTC, the fecal occult blood, PSA, H . pylori, IHC, ISH, and tests for specific cancers: bladder cancer • • • Breast Cancer Cervical Cancer Colon Cancer Lung Cancer • • • • Ovarian Cancer Prostate Cancer This new edition of Kalorama Information study takes a fresh look at all these developments, both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways: • Testing for certain types of cancer, and • Evidence of cancer in segmentsThis DIV allows the reader to match your specific market situation in general. ContentsCHAPTER Table ONE: Executive Summary Introduction Scope and Methodology Size and Growth of test market segments Geographical Distribution trends in mortality rates PriceCHAPTER Medical Therapeutics revolutionary consumer lobby twofold: Introduction Background Screening Cancer pharmacogenomics Marketing Services – Diagnostic and therapeutic management points ViewCHAPTER Three: Demographic trends of the market in the marketing of a history of Cancer Diagnosis cancer, evidence worldwide phenomenon in the worldwide cancer: screening and programs supported by the Government of the United States Mexico China Europe International Marketing Services Reimbursement India and other tests of the trial – to innovation Cancer Table 3-3 Regulatory Requirements for new products, strategic alliances and partnerships in advancing personalized medicine and gene patents Test CommercializationCHAPTER FOUR Revolution: Trends in biomarker technology Background The promise of personalized medicine and miniaturization Multiplexed Biological Assessment Tools The emergence of new non-invasive technology platforms for diagnosing cancer General Mass Spectrometry new chromosomal analysis of next generation sequencing RNA – ribonucleic acid in vitro / in vivo MixCHAPTER FIVE: Market Segment Analysis of the global market for regional funds to businesses in the diagnosis of cancer detection products and has lost its charm? Specific tests for bladder cancer, breast cancer cervical cancer colorectal cancer Lung Cancer Ovarian Cancer Prostate Cancer CancerCHAPTER SIX: Testing of cancer in IVD segments (Segment Analysis) Cancer Diagnosis and markets IVD Testing Market cancer clinical chemistry market of Cancer Immunology Laboratory, and rapid point test market for cancer care in histology / cytology stains traditional Pap test and HPV-tissue IHC / ISH Fabric Market The market for DNA microarrays cancer tests Flow Cytometry Market circulating tumor cells in the diagnosis of Cancer of the market for molecular cancer screening in the market for cancer tests Pharmacognosy market of biochips and arrays in the diagnosis of cancer of the Business Outlook for cancer DiagnosticsCHAPTER SEVEN: Conclusions and Policy Implications Conclusions Conclusion 1 Involvement: Implication 2 Conclusion: Conclusion Conclusion 4 5 Attendance Attendance: Conclusion 6: The unmet market needs unmet # 1 # 2 Unmet need Unmet 3CHAPTER # EIGHT: the top level DIV and investment companies in the diagnosis Cancer Molecular Diagnostics, Abbott Molecular Diagnostics, Beckman Coulter Inc. Immunoassay Histology FOB flow cytometry Becton, Dickinson and Company (BD) Histology bioMérieux Inc. Bio-Rad Laboratories Inc. Dako A / S Fujirebio Diagnostics, Inc. Hologic Inc. Gen-Probe Inc. Inverness Medical Innovations Histology HPV QIAGEN N. Ortho Clinical Diagnostics V Roche Diagnostics Indianapolis, IN www. Roche. com Recent History income ($ millions) immunoassay PCR Histology Research Molecular Diagnostics Siemens Medical Solutions in vivo Sysmex CorporationCHAPTER NEW: The status quo in the diagnosis of cancer diagnosis AdnaGen AG Agendia BV AMDL, Inc. (ADI) American Diagnostica Inc. Aperio Technologies, Inc. Asuragen, Inc. AviaraDx Binding Site (The) Ltd. BioCurex BioGenex Laboratories Inc., Bio-Reference bioimagerie Inc. Laboratories, Inc. Biotage Celera Diagnostics AB bioTheranostics BioView Ltd. China Medical Technologies, Inc. Cisbio Bioassays Clarient Inc. (formerly Chromavision) Clinical Data, Inc. CytoCore, Epigenomics AG, Inc. Imaging Genetix Ltd. DxS Applied Health Genomics, Genetics Inc., Genzyme Corporation HistoRx Discovery Health, Inc. Ikonisys, InterGenetics Lab21 Inc. SA Inc. Ipsogen Health Laboratory Corporation of America Holdings (LabCorp) Life Technologies Monogram Biosciences, Inc. Myriad Genetics mtm laboratories, Inc. Nanosphere, Inc. OncoVista Therapies, Precision Therapeutics Diagnostics Inc. Quest Diagnostics Inc. Pathwork Prometheus Labs genetic response, Rosetta Genomics Ltd. Veridex Sequenom Inc. Transgenomic Inc., Zila Inc. Vermillion LLC, RTE IncCHAPTER: new operators and new product developers GeneSystems 20/20, 454 Life Sciences Corporation Acrometrix Corporation Inc. (Life Tech). Acupath Laboratories, Affymetrix Inc. Advalytix Technologies, Inc. Althea Diagnostics Allegro, Life Sciences Inc. Arbor Vita Corporation Ltd. Amorfix Diagnostics Inc. AVEO Pharmaceuticals Inc. Arraya ArcticDx Biosystems Inc. Axela Inc. Baypoint, Inc. Biodesix, Biologix Diagnostics Inc., biomarker Strategies LLC bioprospecting NB BioMosaics Biomod LLC, Inc. (BPNBI) BioServe SAS Biosystems International (BSI) BioTrove, Inc. Cambridge Research & Instrumentation, Inc. (CRI) Cange Biotechnologies, Inc. Caris Diagnostics Inc. Castle Biosciences Cell Biosciences Celerus CeMines Diagnostics, Inc., Cepheid Inc. Chronix ChromoCure Biomedical Clinical Genomics Pty Ltd CombiMatrix Molecular Diagnostics Inc. (CMDX) Comprehensive Cancer Cell (SAC) Diagnostics Inc. Compugen Ltd. Correlogic Systems, Inc. CS-Keys, Inc. deCODE Genetics Inc. — ASA DiaGenic DiagnoCure – Diagnoplex Diagnosis Biosystems company, DNA Direct, Inc. Diagnostic Biotechnology Corporation Epistem skills EDP Sciences Corp. Plc Exiqon A / S ExonHit Therapeutics Inc expression diagnostic pathology exosome Inc. Falcon Genomics, Inc. FASGO Diagnostics, Therapeutics LLC Foligo Fluxion Biosciences, Inc. Genoptix Gastrocor GENELEX Corporation Limited GeneNews Diagnosis iKaryos Inostics Illumina Technologies International GmbH B. V Bioprobes intrinsic Invirion Diagnostics Inc., InVivoScribe Iris Technologies Inc. LLC IRIS International Biotechnologies, Inc. MabCure macroarrays Technologies Inc., LLC Biosystems Inc. MagArray Martell, Inc. biogenic Med, Inc. (MBI) Metabolon forecast Medical Institute, Inc. Miraculins Neogenix Oncology Inc. MolecularMD Corp., Inc. NextGen Sciences Nuvera Biosciences AB LLC Oncimmune Olinka S. OncoMethylome Sciences An Orion Genomics-Q-tion of Oxford Pacific Rim Biotechnology Biotherapeutics Ltd. (ILL) PhotoCure ASA Power3 Medical Products, Inc. Health Sciences Predictive Biosciences PrognosDx forecasts, Inc., Provista Life Sciences LLC Rubicon Genomics, Inc. Rules Based Medicine Inc.. (GFR) Saladax Biomedical, Inc. (SBI) SensiGen cancer diagnostic laboratories LLC Sienna Signature Genomics, Inc. Diagnostics LLC Singulex horizon B. Source MDx biodynamics Soar V, Inc. Strategic Diagnostics Ltd. Synergenz Bioscience Ltd. Directed molecular diagnostics (TDG) Theranostics Health (TH) TrimGen TrovaGene Corporation, Inc. Inc. Vitatex WaferGen Biosystems, Inc. Xceed Molecular (formerly MetriGenix Corporation) Zetiq Technologies Ltd.

Comments are closed.